Letter from the Editor

The ADA Scientific sessions are underway in Orlando and Steve Freed and Joy Pape, along with our two interns Kaytie and Kennen, and guest Michele Laine, ARNP, CDE, are there to cover all the latest in diabetes, and interview the thought leaders on where diabetes care is and where it is going over the next 1-3 years.

Please check out our Newsflashes to see what we have learned already and then take a look at our feature article by our Doctor of Pharmacy Candidate, Kennen Munoz Munoz, as he delivers info on one of the hottest topics of discussion, the use of a GLP-1 agonist along with an SGLT-2 Inhibitor.

As Barney Stinson once said on the hit show How I Met Your Mother: “It’s gonna be legen — wait for it … and I hope you’re not lactose-intolerant ’cause the second half of that word is — dary!”

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Newsflash: ADA Breaking News

The FDA approved the first long-term implantable continuous glucose monitor (CGM) on Friday, the maker Senseonics announced. The Eversense CGM System features an implantable glucose sensor that can remain in place for up to 3 months, beating out the usual wear time of 3-10 days for many of the other CGMs currently available.

Coming Soon! Watch for our Special Edition of Breaking News from the ADA 78th Scientific Sessions with interviews from the major presenters.

This Week's Survey

Would you feel comfortable using a combination treatment of a GLP-1 receptor agonist and a SGLT-2 inhibitor for a patient who has not reached goal? Follow the link to respond.

Newsflash: FDA Approves Minimed 670G System for Children 7-13

FDA approval was based on positive results from a pediatric clinical trial, which demonstrated the safety of the MiniMed 670G system in this younger patient population. The MiniMed 670G system is commercially available for immediate shipment to patients interested in transitioning to the system.

GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several naturally occurring incretin compounds that affect the body after they are released from the gut during digestion. By binding and activate GLP-1 receptors, GLP-1 agonists, and endogenous GLP-1 are capable to reduce blood glucose levels helping T2DM patients to reach a glycemic control. Download the chart of currently available GLP-1 drugs.

Test Your Knowledge

You are concerned about Mr. Carlson’s cigarette use because cigarette smoking has been shown to have multiple physiological impacts on health. Which one of the following statements regarding smoking and type 2 diabetes is true?

A. It equally affects all-cause mortality in individuals with and without diabetes
B. In individuals with diabetes, it causes more rapid progression to micro- and macroalbuminuria
C. It has not been linked to worsening glycemic control
D. The use of bupropion in contraindicated in diabetes

The ADA Scientific sessions are underway in Orlando and Steve Freed and Joy Pape, along with our two interns Kaytie and Kennen, and guest Michele Laine, ARNP, CDE, are there to cover all the latest in diabetes, and interview the thought leaders on where diabetes care is and where it is going over the next 1-3 years.

Please check out our Newsflashes to see what we have learned already and then take a look at our feature article by our Doctor of Pharmacy Candidate, Kennen Munoz Munoz, as he delivers info on one of the hottest topics of discussion, the use of a GLP-1 agonist along with an SGLT-2 Inhibitor.

As Barney Stinson once said on the hit show How I Met Your Mother: “It’s gonna be legen — wait for it … and I hope you’re not lactose-intolerant ’cause the second half of that word is — dary!”

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Newsflash: ADA Breaking News

The FDA approved the first long-term implantable continuous glucose monitor (CGM) on Friday, the maker Senseonics announced. The Eversense CGM System features an implantable glucose sensor that can remain in place for up to 3 months, beating out the usual wear time of 3-10 days for many of the other CGMs currently available.

Coming Soon! Watch for our Special Edition of Breaking News from the ADA 78th Scientific Sessions with interviews from the major presenters.

FDA approval was based on positive results from a pediatric clinical trial, which demonstrated the safety of the MiniMed 670G system in this younger patient population. The MiniMed 670G system is commercially available for immediate shipment to patients interested in transitioning to the system.

GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several naturally occurring incretin compounds that affect the body after they are released from the gut during digestion. By binding and activate GLP-1 receptors, GLP-1 agonists, and endogenous GLP-1 are capable to reduce blood glucose levels helping T2DM patients to reach a glycemic control. Download the chart of currently available GLP-1 drugs.

You are concerned about Mr. Carlson’s cigarette use because cigarette smoking has been shown to have multiple physiological impacts on health. Which one of the following statements regarding smoking and type 2 diabetes is true?

A. It equally affects all-cause mortality in individuals with and without diabetes
B. In individuals with diabetes, it causes more rapid progression to micro- and macroalbuminuria
C. It has not been linked to worsening glycemic control
D. The use of bupropion in contraindicated in diabetes